Physician profile

Faisal Fakih

Winter Park, FL

NPI 1386635480

$7,516.96

in general payments reported to CMS, 2019-2025

27 companies · none reported in 2025

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$2,080.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Regeneron Pharmaceuticals, INC. $2,133.13 2022-2024
Astrazeneca Uk Limited $1,798.18 2019
Astrazeneca Pharmaceuticals LP $1,255.35 2019
Novartis Pharmaceuticals Corporation $1,138.70 2019-2020
Merck Sharp & Dohme LLC $1,136.21 2019
Travere Therapeutics, INC. $41.59 2019
Pfizer INC. $13.80 2019

20 companies reported research payments only; those appear in the research section below.

Research and ownership

$4,076.27 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Faisal Fakih

$7,516.96

in general payments reported 2019-2025

Years
2019-2024
Top company
Takeda Pharmaceuticals U.S.A., INC.

https://glasscript.com/doctor/244019/faisal-fakih

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.